Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET-CTReportar como inadecuado




Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET-CT - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Musculoskeletal Disorders

, 15:393

Clinical diagnostics and imaging

Abstract

BackgroundPositron emission tomography PET with 2-18F-fluoro-2-deoxy-D-glucose F-FDG can detect the presence of synovitis in rheumatoid arthritis RA patients. The aim of this study was to investigate whether the findings of FDG-PET matched the conventional assessments of the disease activity score DAS 28, DAS28-CRP, simplified disease activity index SDAI and clinical disease activity index CDAI in RA patients receiving tocilizumab TCZ therapy.

MethodsSeventeen RA patients treated with TCZ were assessed. FDG-PET was performed at baseline and three and six months after the initiation of TCZ therapy. The maximum SUV SUVmax of the bilateral shoulder, elbow, wrist, hip, knee and ankle joints were added together total SUV and were used to assess the degree of FDG uptake as a representative parameter. The correlations between the ΔSUV and the difference in the clinical parameters at baseline and at each observation period, and the differences in each clinical parameters, were assessed.

ResultsThe ΔSUV, the differences in the total SUV at baseline and at three-six months after starting treatment positively correlated with the ΔDAS28 r = 0.615 p = 0.009- r = 0.775 p < 0.001, ΔDAS28-CRP r = 0.696, p = 0.002- r = 0.828, p < 0.001, ΔSDAI r = 0.652, p = 0.005- r = 0.686, p = 0.002 and ΔCDAI r = 0.662, p = 0.004- r = 0.711, p = 0.001 for each period. The total SUV was significantly decreased at three and six months after the initiation of TCZ p < 0.05.

ConclusionsA reduction in the FDG uptake was observed at three and six months after the initiation of TCZ therapy. The disease activity estimated on FDG-PET-CT matched the conventional parameters following the TCZ therapy in RA patients.

KeywordsRheumatoid arthritis Interleukin-6 Positron emission tomography SUV Synovitis Tocilizumab Electronic supplementary materialThe online version of this article doi:10.1186-1471-2474-15-393 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Koichi Okamura - Yukio Yonemoto - Chisa Okura - Tetsuya Higuchi - Yoshito Tsushima - Kenji Takagishi

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados